Novo Nordisk A/S: Replicate Bioscience announces partnership with Novo Nordisk to unlock self-replicating RNA therapies for obesity and diabetes (56.44)
- Replicate Bioscience, a clinical-stage company pioneering next-generation self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas, today announced a multi-year research collaboration with Novo Nordisk. This collaboration unites Novo Nordisk's deep therapeutic knowledge and drug development expertise with Replicate's novel srRNA platform to develop new therapeutic candidates to treat obesity, type 2 diabetes and other cardiometabolic diseases.
- Under the terms of the agreement, Novo Nordisk and Replicate will collaborate on certain targets for cardiometabolic diseases. Novo Nordisk will receive a defined exclusive, worldwide license to use Replicate's srRNA platform to develop and commercialize the lead programs. Replicate will receive research funding and is eligible to receive up to US$550 million from Novo Nordisk. This includes an up-front cash payment and potential milestone payments. Replicate is also eligible to receive tiered royalties on future product sales as part of the multi-year deal.